GSK may cut 1,217 jobs in Belgium
The reorganisation affects several Belgian sites, according to the company, but definitive redundancies have not yet been determined.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
GSK has announced a reorganisation in Belgium that could affect up to 1,217 jobs. According to the company, the positions are spread across several sites; factory workers would be excluded from the plan.
The British pharmaceutical company informed Belgian trade unions of its plans on Wednesday during an extraordinary works council meeting. According to Reuters, GSK said the reorganisation could affect up to 1,217 employees. The plan is therefore not yet a final redundancy list.
According to Belgian reports, the activities concerned are located in Wavre, Rixensart and Gembloux. TVcom writes, based on information from RTBF, that the figure comprises 482 clerical employees and 735 managerial staff. Production workers would not be affected by the proposed reorganisation, according to the company statement.
GSK refers to a restructuring of certain activities. The available information does not yet provide a complete picture of which research teams, support functions or production units will be adjusted. Nor is it yet known how many jobs will ultimately disappear after consultations with employee representatives have concluded.
In Belgium, the so-called Renault procedure applies to collective redundancies. The procedure provides for information and consultation with employee representatives. According to local reports, options to prevent redundancies or limit their number, and to mitigate the effects on employees, are to be examined in the coming weeks.
The announced reorganisation is relevant to the European pharmaceutical sector because Belgium is an important location for research, vaccines and production. The available sources do not indicate that the reorganisation will already affect the supply of vaccines or medicines in the Netherlands. No specific statement has been made on that point.
The trade unions are expected to ask questions about the reasons for the intervention and previous public support for the sector. That debate is separate from the formal redundancy procedure. For now, the only certainty is that GSK has announced a plan; the scale and precise distribution of the eventual job losses may still change.
One story, several perspectives
What is established
- GSK has announced a reorganisation plan that could affect up to 1,217 jobs in Belgium.
- The formal information and consultation procedure has begun.
- The final number of redundancies and the precise roles involved have not yet been determined.
Left
Arguments A company that receives public support and makes socially important medicines should preserve jobs and expertise as far as possible. Employees and the government may demand alternatives and repayment of support.
Values Job security, public responsibility and protection of strategic healthcare capacity.
Consequences More conditions attached to support could limit redundancies, but could also make companies’ investment decisions more complicated.
Centre
Arguments The procedure must first be followed carefully. Competitiveness, research and employment should be considered together; consultation can determine which roles are genuinely needed.
Values Social dialogue, fact-finding and preservation of a viable sector.
Consequences A negotiated reorganisation can limit social harm without forcing a company to continue activities that are not economically sustainable.
Right
Arguments A company must be able to adapt its organisation to market developments and international competition. Governments should be cautious about prescribing business decisions.
Values Entrepreneurship, economic flexibility and the responsibility of shareholders and management.
Consequences Greater scope for restructuring can make the company more competitive, but means short-term uncertainty for employees and regions.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The reporting is based on Reuters, local Belgian media and a trade union source. The article presents the figure as a maximum and makes clear that the redundancies are not yet final.
- confirmed GSK announced a plan in Belgium that could affect up to 1,217 jobs. — GSK confirmed the plan, according to Reuters. source
- confirmed The reorganisation concerns sites in Wavre, Rixensart and Gembloux. — Mentioned in Belgian reporting. source
- confirmed According to the available reporting, the plan mainly affects clerical employees and managerial staff, not factory workers. — Reuters reports that factory workers are not affected; TVcom gives the breakdown. source
- confirmed Consultation in Belgium is proceeding under the Renault procedure. — Local reporting and the trade union source say that this procedure has begun. source
Editor's note
What has been confirmed is an announced reorganisation plan that could affect up to 1,217 employees. The final scale, roles involved and impact on production are still subject to consultation.Sources
- GSK to cut up to 1,217 jobs in Belgium — Reuters via MarketScreener
- 1217 emplois menacés chez GSK — TVcom
- GSK restructureert en ontslaat 1.217 werknemers — BBTK Leuven
More on this in Dutch media
- Trouw — „gsk belgië”
- RTL Nieuws — „gsk belgië”
- FD — „gsk belgië”